Orencia Approval History

• FDA approved: Yes (First approved December 23rd, 2005)
• Brand name: Orencia
• Generic name: abatacept
• Company: Bristol-Myers Squibb Company
• Treatment for: Rheumatoid Arthritis

Orencia (abatacept) is a selective costimulation modulator indicated for the treatment of rheumatoid arthritis (RA).

FDA Approval History for Orencia

Date	Article
Jul 31, 2011	U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
Dec 23, 2005	Orencia Bristol-Myers Squibb Company - Treatment for Rheumatoid Arthritis
Sep  6, 2005	Bristol-Myers Squibb Statement on FDA Advisory Committee Vote on Orencia (Abatacept), an Investigational Selective Modulator of T-Cell Co-Stimulation for Rheumatoid Arthritis
Dec 23, 2004	Bristol-Myers Squibb Provides Regulatory Update for Abatacept

See also...

Orencia (abatacept) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.